1385 results about "Drugs preparations" patented technology

A pharmaceutical system and method of operation in which a single remote professional provides pharmaceutical care and oversight of multiple local pharmacies. A control location is connected through an electronic network to one or more individual pharmacies, each of which may be located at a different physical site. Each individual pharmacy includes one or more drug preparation areas, and one or more self-service or staffed customer terminals. A drug preparation area includes a robot, which is adapted to prepare prescriptions or other items, and which is connected by a pneumatic delivery system to one or more customer terminals within the pharmacy.

A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.

Topical gelled compositions comprising a drug which causes vasodilation, and optionally prostaglandin E1, dispersed within a polymer matrix, and methods of treating sexual dysfunction, including both male and female sexual dysfunction, using said compositions.

The invention relates to a pharmaceutical composition for administering the dopamine agonist N-0923 in depot form. The invention makes available for the first time a depot form of N-0923, which achieves a therapeutically significant plasma level over a period of at least 24 hours after administration to a patient. As a result of poor oral bio-availability and the short plasma half-life, N-0923 was previously administered either by an intravenous drip or by transdermal systems. Preferred embodiments of said invention are oily suspensions, containing the active ingredient N-0923 in a solid phase, in addition to anhydrous pharmaceutical preparations of N-0923.

The invention discloses a Chinese medicinal plaster for curing orthopaedics disease and the preparing method thereof, characterized by that it uses several ones of black-bone chicken, Chinese Angelica, Notoginseng powder,Myrrha, Rhizoma Drynariae, Dragon's Blood, Radix Curcumae, Common Burreed Rhizome, Zedoary, Giant Knotweed Rhizome, Ground Beeltle, Pyrite, and Frankincense as principal drugs and selects parts of 97 Chinese drugs such as Long-nosed Pit Viper, Earthworm, Dragon's Blood, Prepared ChuanWu, Pangolin Scales, Doubleteeth Pubesscent Angelica Root, Rhizoma Corydalis, Himalayan Teasel Root, Cortex Cinnamomi Cassiae, Flos Caryophylli, and Borneol as adjuvant drugs, according to different properties of Chinese drugs, fries partial medicinal materials, decocts partial light and strongly fibrous medicinal materials with water for three times, concentrates the decoction into extract, dries and crushes the extract into fine powder, and adds the fine powder into medicinal oil added with pills; and finally adds in powder of partial fine materials. Its formula and preparing method are peculiar and it is an ideal traditional external drug preparation for curing orthopaedics disease.

The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I):

wherein A, R², and X are as defined in the specification; or a salt thereof.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to an actuator having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

A cosmetic, dermatological or pharmaceutical preparation comprising from 10% to 99% by weight of one or more lipids, from 1% to 90% by weight of one or more waxes and at least 20% by volume of one or more gases.

Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

The invention provides a new liquid aqueous drug preparation of an anti-TNF (tumor necrosis factor)-alpha human monoclonal antibody for strengthening the stability, wherein antibody solution is stabilized and osmotic pressure is regulated by sorbitol; disodium hydrogen phosphate/citric acid monohydrate or sodium acetate/acetic acid is taken as a buffer agent, and preferably, the disodium hydrogen phosphate/citric acid monohydrate is taken as the buffer agent; and tween-20 is taken as a surfactant, so that antibody preparation is stable, and long in retention time, meanwhile, preparation components are simplified, and the preparation is prepared simply and conveniently.

The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines or amino thiols formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.

The invention provides processes to make slowly digestible starches from native and commercial starches. Slowly digestible starches are prepared by controlled hydrolysis of gelatinized starch by alpha amylase. The slowly digestible starches have a range of starch digestion rates and fall between normal, untreated commercial and native starch, and commercial resistant starches. The slowly digestible starches provide a range of starch functionalities. These slow digesting starches retain their digestion characteristic after cooling, and can used in a range of processed food products to modulate the rapid glucose release typical of many processed starchy foods. Edible products incorporating slowly digestible starch will exhibit lower glycemic index and increase satiety. The invention provides solid and liquid food, nutritional, and drug preparations containing the slowly digestible starch. The invention further provided edible products for extended energy release for example, for use in sports drinks and snack bars. The slowly digestible starches can also be employed as functional food grade additives to provided beneficial rheological or other properties to edible compositions.

The invention discloses a multifunctional medical service system. The system comprises a medical server, repeater equipment, a medical detection instrument, terminal recognition equipment and intelligent equipment. The system has the functions of intelligent alarming, registration appointment, intelligent reception, intelligent salvation, intelligent queuing, intelligent navigation, intelligent calling, intelligent drug preparation, intelligent payment, intelligent reimbursement, intelligent charging, intelligent health guidance, medical information checking, etc., it is convenient for medical personnel, patients and family members to monitor patient conditions anytime, it is convenient for a hospital to recognize the patients, it is convenient for the patients and the family members to quickly handle all affairs in the hospital, time is saved for the patients, the work efficiency of the hospital is improved, and the system can be generally used in all large hospitals nationwide, is used for establishing a unique archive for health management of a patient and brings great convenience to people.

The invention provides a pyrazolopyrimidine compound shown as a structural formula (I), a pharmaceutical composition taking the pyrazolopyrimidine compound as an active component, a preparation method of the pyrazolopyrimidine compound and the pharmaceutical composition as well as an application of the pyrazolopyrimidine compound and the pharmaceutical composition in preparation of a TRPC6 (Transient Receptor Potential Channel 6) adjustor probe medicine and related medicines for preventing and treating glomerulopathy and myocardial hypertrophy. The pyrazolopyrimidine compound and derivatives provided by the invention can be used to prepare medical preparations in various forms which comprise oral liquids, injections, pulmonary inhalation preparations and transdermal preparations, specifically injections, oral liquids, troches, capsules, granules, aerosols, dry powder inhalation, patches and the like.

The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.

The invention belongs to the technical field of medicine, particularly relates to a heterocyclic nitrogen compound which acts as a tyrosine kinase inhibitor and is represented by a general formula (I) as well as a deuterated material, pharmaceutically acceptable salt or stereisomer thereof. In the general formula (I), X, W, R1, R2, R3, L1, L2, a, b, c, d, e, p, q, a ring A and a ring B are defined in specification. The invention further relates to a preparation method of the compounds, a pharmaceutic preparation containing the compounds, and important actions of the compounds in treatment of leukemia (such as B cell chronic lymphocytic carcinoma and non-hodgkin lymphoma) related to B cell, and autoimmune diseases (such as rheumatoid arthritis and systemic lupus erythematosus).

The present invention relates to phenyl or heteroaryl amino alkane derivatives of formula (I)

in which the groups Q¹-Q⁴, Ar, and R¹-R⁷ are as defined in the specification and claims. These materials are useful as active ingredients of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorders as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since these diseases also are alleviated by treatment with an IP receptor antagonist. The application claims the compounds, pharmaceutical compositions containing them, and methods of treatment using them.

The disclosed antibody special for beta-amyloid polypeptide has amino acid sequence and the coded nucleotide sequence shown as SEQ ID No.2 and SEQ ID No.1 respectively, and can be used to prepare drug to cure or prevent senile dementia.

Tetrahydropiperine and analogs and derivatives thereof, including dihydropiperine, are disclosed to enhance the absorption and/or bioavailablity of nutrients, drugs and other organic compounds, such as insectides.

The invention relates to the pharmaceutical chemistry filed, and particularly relates to novel nitric oxide donor butyl phthalide derivatives (I), the preparation method thereof, a drug preparation containing the derivatives (I) and the application as a drug for resisting thrombosis and cerebral ischemia. Wherein, the definitions of R and A are shown in the instruction.

A safflower lyochrome rich is carthamin A (80-100%) and its preparing process and application to preparation of medicines to prevent and cure cardiovascular and cerebrovascular ischemia, and its medicines and preparing process are also disclosed.

The invention relates to a pharmaceutical composition for treating excessive proliferation diseases, and belongs to the field of pharmaceutical preparations. The pharmaceutical composition comprises active ingredients which include 1-[(3R)-3-[4-amino-3-(4-phenoxy phenyl)-1H-pyrazol[3,4-D]pyrimidine-1-group]-1-piperidyl]-2-propylene-1-ketone, a solvate of 1-[(3R)-3-[4-amino-3-(4-phenoxy phenyl)-1H-pyrazol[3,4-D]pyrimidine-1-group]-1-piperidyl]-2-propylene-1-ketone, a hydrate and salt acceptable in pharmacy or a composition of the salt and at least one excipient acceptable in pharmacy; and the active ingredients at least occupies 30% of the composition. The pharmaceutical composition is easy to swallow; the number of times of drug feeding is decreased; the compliance of a patient can be obviously improved; in addition, the pharmaceutical composition has the good dissolution characteristic, the excellent bioavailability, the high stability and the sufficient hardness; and the pharmaceutical composition is suitable for clinic treatment of cancers. The preparation method of the pharmaceutical composition is simple and practical, and the pharmaceutical composition is suitable for industrial production.

Provided are a system and method for presenting information related to a drug dilution. A computer memory stores a drug database with a plurality of drug entries, each of which includes an identification and concentration of a drug stored in an originating container. A reader is operable to read a barcode associated with the drug identifier of the originating drug container and the concentration and/or dose and volume of the drug in the container. A user selects or enters a desired drug preparation that may include one or more preparations of the originating drug requested for administration to a patient. A computer processor interprets the concentrate signal, identifies the concentration of the originating drug based on content included in the drug database, and determines a recipe to be presented to the user for preparing the drug including any required dilutions.

A sheet-form adhesive preparation which gives a comfortable refreshing feeling in use, gives a wet feeling to the skin, and is usable a a cosmetic, medicinal, or quasi-drug preparation for the sake of skin adjustment and beauty. The preparation preferably has a quantity of heat required for water evaporation of 0.6 to 13 (cal) per unit area (cm²) when exposed for 30 minutes to an atmosphere of 25° C. and 60% Rh.

The invention discloses a novel cationic liposome, a cationic liposome nucleic acid pharmaceutical preparation having the same as well as a preparation method and application thereof. The cationic liposome comprises cationic lipid, assisted lipo, polycarboxyl betaine lipid molecule and a freezing protective agent. The cationic liposome nucleic acid pharmaceutical preparation comprises cationic liposome modified by neutral lipid of polycarboxyl betaine and nucleic acid pharmaceutical preparation working solution. According to the cationic liposome, the defects of high toxicity, bad blood stability and low transfection efficiency are overcome and the pharmaceutical effects of the nucleic acid drugs are effectively improved; and at the same time, as the preparation is undisturbed by blood serum during the use, the operations in the experiment and the treatment are simplified.

The invention discloses a fucose sulfate or a compound whose active component is fucose sulfate, in the drug preparation on the treatment of nerve retrograde disease and cognition damage. And the invention discloses the relative application. The inventive fucose sulfate is mainly from marine invertebrate animal as sea-tangle, sea cucumber or the like, with wide resource, easy production, batch production, and wide application.

The invention relates to an injection device for medical drug preparation. The injection device comprises a supporting base plate, an overall rotary motor, an injector feeding mechanism and a mandrel push-and-pull mechanism, wherein a feeding motor of the injector feeding mechanism drives a feeding screw to rotate through a coupler, so that a feeding nut drives a feeding sliding block to move up and down along the feeding screw to drive an injector outer sleeve to conduct translational movement in the axial direction of the injector outer sleeve; and a push-and-pull motor of the mandrel push-and-pull mechanism drives a push-and-pull screw to rotate through a coupler, so that a push-and-pull nut drives a push-and-pull sliding block to move up and down along the push-and-pull screw, a mandrel clip fixed on the push-and-pull sliding block drives an injector mandrel to move up and down relative to the injector outer sleeve, and injector push-and-pull actions are finished. The injection device is compact and reasonable in structure, convenient to operate and capable of performing automatic operation on a disposable injector, realizing functions of liquid extraction, liquid injection, transposition, pipetting and the like required in a drug preparation process, lowering the human intervention degree, reducing the labor intensity and avoiding drug waste and cross contamination.

When drugs are prepared according to drug preparation order sheets printed by drug preparation order printers, it is desired to freely set the relation with the printers by setting data without directly connected and fixed to a control program of a control unit of a drug preparation order system so as to cope with e.g. relocations of drug preparation tables. As the drug preparation instruction system, a control unit and a plurality of drug preparation order printers are provided. In the data storage portion of the control unit, data showing the relation between drugs and drug types are stored. By reading drug type codes from inputted drug data, and by reading printer numbers corresponding to the respective drug type codes from a printer setting portion in which are stored data showing the relation between drug type codes and printer numbers, drug data are printed individually by the printers of the set numbers.

The invention relates to a compound shown as formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof. R1, R2, R3, R4, m, n, W, A, Z, E, F, X and Y are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations and application in drugs for treatment and/or prevention of FXR (farnesoid X receptor) mediated nonalcoholic fatty liver diseases, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications, malignant tumors and other related diseases. (formula (I)).